Member Directory
I am a freelance consultant and a science and medical writer. I trained in physics before switching to biophysics for my PhD (later bioinformatics) and spent nine years as a postdoctorate in the UK and US before changing careers in 1998. I still teach to MSc level; bioinformatics and structural biology at Birkbeck, University of London and medicinal chemistry at the Opeu University. I write news and features in print and online for a specialist scientific and medical readership; provide specialist editing services; and offer support, training and capacity building in bioinformatics and related subjects within academia and industry.
Custom Pharma Services (CPS) as a strategic business unit of Dr Reddy’s draws on years of knowledge and expertise in pharmaceutical development and manufacturing to provide innovators with customised services and solutions for intermediates, active ingredients and finished dosages. Within a short span, we have become one of the largest pharmaceutical outsourcing players from India and a global partner-of-choice. We have a track record of bringing innovations to the market quickly, efficiently and economically with the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. Our end-to-end services make a compelling value proposition to our global innovator customers.
Eagle Genomics innovates at the intersection of biology, data sciences and bioinformatics to develop technical solutions and enterprise information architecture for the microbiomics and genomics era. . . Eagle’s knowledge discovery platform, the e[automateddatascientist], uses machine learning to transform raw data into actionable insights that drive scientific decision making, enabling companies to make more credible scientific claims, enhancing R&D processes and brand perception. . . Eagle’s smart data management solutions and unique expertise gives access to insight that enables quick assessment of product potential, mitigates risks and reduces time to market at many sciences companies across industries including pharmaceutical, biotechnology, crop science, personal hygiene and animal health.
The Earlham Institute (EI) is a research institute applying advanced genomics and computational approaches to aid our understanding of complex biological systems and their interaction with the environment.
Established in 2009 and located on the Norwich Research Park, EI is strategically funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).
The Earlham Institute (EI) uses expertise in genomics, bioinformatics and molecular biology to answer complex biological questions and improve plant and animal health, and tackle global issues of food security, climate change, conservation and human wellbeing.
EI is home to state-of-the-art laboratories, specialist equipment and facilities enabling genomics and bioinformatics research, including one of the largest supercomputing facilities for life science research in Europe.
Our technology platforms include:
• Genomics and Single-Cell Analysis facility that provides scalable infrastructure for high-throughput DNA/RNA analysis of biological systems.
• BIO Foundry facility that provides services for high-throughput, nanoscale DNA-assembly, low-cost sequence validation of synthetic constructs and microfermentation.
• High-Performance Computing platform that provides access to high-throughput computing clusters and data management support.
• State-of-the-art training facility for bioinformatics and genomics with expert-led courses.
EI has established collaborative projects worldwide. We are involved in collaborative R&D projects with industry through consultancy, contract research, and grant funding.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:. •
eLabNext is your partner in lab digitization. Their centralized Digital Lab Platform enables scientists to optimize laboratory processes and accelerate research discoveries. Maximize capabilities by integrating free add-ons from Marketplace or develop your own with eLab APIs & SDKs. Their team of friendly experts are always ready to assist you and your team. eLabNext is a brand of Bio-ITech BV, part of Eppendorf Group.
Watch their video here:
https://youtu.be/bdQzm732k2Q
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.